Arvinas Inc
ARVN7.810USD
+0.580+8.02%
Market hours （ET）Quotes delayed by 15 min
537.33MMarket Cap
LossP/E TTM
More Details of Company
Company Info
Company codeARVN
Company name- -
IPO date- -
Founded at- -
CEO- -
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address- -
City- -
Stock exchangeNASDAQ Global Select Consolidated
Country- -
Postal code- -
Phone- -
Website- -
Company codeARVN
IPO date- -
Founded at- -
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
986.41K
+13.94%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
110.02K
-7.30%
Dr. Ian Taylor, Ph.D.
Dr. Ian Taylor, Ph.D.
President - Research and Development
President - Research and Development
105.53K
+12.35%
Dr. Angela Cacace
Dr. Angela Cacace
Chief Scientific Officer
Chief Scientific Officer
96.74K
+86.56%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
5.90K
--
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
5.90K
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
5.90K
--
Mr. Jared Morris Freedberg
Mr. Jared Morris Freedberg
General Counsel
General Counsel
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
John Young ,
John Young ,
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
986.41K
+13.94%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
110.02K
-7.30%
Dr. Ian Taylor, Ph.D.
Dr. Ian Taylor, Ph.D.
President - Research and Development
President - Research and Development
105.53K
+12.35%
Dr. Angela Cacace
Dr. Angela Cacace
Chief Scientific Officer
Chief Scientific Officer
96.74K
+86.56%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
5.90K
--
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
5.90K
--
Revenue Breakdown
FY2024
FY2023
No Data
By RegionUSD
Name
Revenue
Proportion
United States
263.40M
0.00%
By Business
By Region
No Data
Shareholder
Update time: Fri, Feb 28
Update time: Fri, Feb 28
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
11.46%
EcoR1 Capital, LLC
9.22%
BlackRock Institutional Trust Company, N.A.
7.24%
T. Rowe Price Associates, Inc.
5.51%
Citadel Advisors LLC
4.77%
Other
61.81%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
11.46%
EcoR1 Capital, LLC
9.22%
BlackRock Institutional Trust Company, N.A.
7.24%
T. Rowe Price Associates, Inc.
5.51%
Citadel Advisors LLC
4.77%
Other
61.81%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
40.57%
Investment Advisor
35.44%
Hedge Fund
18.71%
Corporation
4.76%
Venture Capital
3.17%
Research Firm
2.67%
Individual Investor
2.42%
Sovereign Wealth Fund
1.70%
Private Equity
1.52%
Institutional Shareholding
Update time: Mon, Mar 3
Update time: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
493
81.65M
117.98%
-2.97M
2024Q4
505
80.31M
116.78%
-4.24M
2024Q3
496
79.95M
116.50%
-140.10K
2024Q2
489
78.26M
114.11%
+1.71M
2024Q1
494
75.44M
110.48%
+3.48M
2023Q4
497
68.16M
100.81%
+12.55M
2023Q3
472
52.04M
94.71%
-3.94M
2023Q2
473
53.77M
100.76%
-3.55M
2023Q1
475
55.60M
104.22%
-4.17M
2022Q4
484
56.43M
106.14%
-6.62M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
7.05M
10.26%
+56.56K
+0.81%
Dec 31, 2024
EcoR1 Capital, LLC
6.73M
9.78%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.29M
7.69%
+152.31K
+2.97%
Dec 31, 2024
T. Rowe Price Associates, Inc.
4.02M
5.85%
+289.37K
+7.75%
Dec 31, 2024
Citadel Advisors LLC
3.48M
5.06%
+407.46K
+13.26%
Jan 30, 2025
Pfizer Inc
3.46M
5.03%
--
--
Dec 31, 2024
RTW Investments L.P.
3.33M
4.85%
+551.98K
+19.84%
Dec 31, 2024
Bellevue Asset Management AG
2.39M
3.47%
+3.00K
+0.13%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
2.21M
3.21%
+2.21M
--
Dec 31, 2024
UBS Financial Services, Inc.
2.01M
2.93%
+1.54M
+329.49%
Dec 31, 2024
View more
Related ETFs
Update time: 10 hours ago
Update time: 10 hours ago
Name
Proportion
SPDR S&P Pharmaceuticals ETF
1.93%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.35%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Range Cancer Immunotherapy ETF
0.49%
Tema Oncology ETF
0.39%
Federated Hermes MDT Small Cap Core ETF
0.19%
iShares U.S. Pharmaceuticals ETF
0.18%
Zacks Small/Mid Cap ETF
0.16%
JPMorgan Fundamental Data Science Small Core ETF
0.13%
Tema Neuroscience and Mental Health ETF
0.13%
View more
SPDR S&P Pharmaceuticals ETF
Proportion1.93%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.35%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.86%
Range Cancer Immunotherapy ETF
Proportion0.49%
Tema Oncology ETF
Proportion0.39%
Federated Hermes MDT Small Cap Core ETF
Proportion0.19%
iShares U.S. Pharmaceuticals ETF
Proportion0.18%
Zacks Small/Mid Cap ETF
Proportion0.16%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.13%
Tema Neuroscience and Mental Health ETF
Proportion0.13%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data